Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Disease progression in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib has been attributed to histologic transformation or acquired mutations in BTK and PLCG2. The rate of resistance and clonal composition of PD are incompletely characterized. We report on CLL patients treate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Ahn, Inhye E., Underbayev, Chingiz, Albitar, Adam, Herman, Sarah E. M., Tian, Xin, Maric, Irina, Arthur, Diane C., Wake, Laura, Pittaluga, Stefania, Yuan, Constance M., Stetler-Stevenson, Maryalice, Soto, Susan, Valdez, Janet, Nierman, Pia, Lotter, Jennifer, Xi, Liqiang, Raffeld, Mark, Farooqui, Mohammed, Albitar, Maher, Wiestner, Adrian
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356450/
https://ncbi.nlm.nih.gov/pubmed/28049639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-06-719294
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars